What is a rare disease therapy worth? David Lapidus discusses this pivotal question for pharmaceutical companies.
Read More
At this year’s J.P. Morgan Healthcare Conference, David Lapidus spoke with biopharma investors about our nation’s new leader. Here’s what happened.
In this series, David Lapidus talks with members of the Rare Collective to debunk common myths surrounding rare diseases. In this post, Chris Smith flips the script on David for his thoughts, and David talks about the challenges of estimating a treatable population.
In this series, David Lapidus talks with members of the Rare Collective to debunk common myths surrounding rare diseases. In this post, Jean Campbell talks about when orphan drug companies should begin interacting with the patient community.
In this series, David Lapidus talks with members of the Rare Collective to debunk common myths surrounding rare diseases. In this post, Chris Smith shares how our understanding of rare disease is evolving, and why it may be a misleading term.
RARE COLLECTIVE® is a trademark of Rare Collective, LLC. 